Moleculin Biotech, Inc. — Q1 2020 Form 10-Q
Business context and reporting period. The filing covers the unaudited quarter ended March 31, 2020, compared with Q1 2019. Moleculin is a clinical-stage biotechnology company developing oncology drug candidates and exploring antiviral applications; it reported no product revenue. Its principal clinical programs included Annamycin, WP1066 and WP1220, with WP1122 also advanced for preclinical antiviral research.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 or prior balance-sheet date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.206 million | $2.932 million |
| General and administrative expense | $1.810 million | $1.591 million |
| Total operating expenses / operating loss | $5.062 million / $(5.062) million | $4.571 million / $(4.571) million |
| Net loss | $(1.209) million; $(0.02) per share | $(4.041) million; $(0.14) per share |
| Operating cash used | $4.342 million | $3.847 million |
| Cash and cash equivalents | $11.649 million | $10.735 million at Dec. 31, 2019 |
| Total assets / total liabilities | $25.472 million / $10.180 million | $25.235 million / $9.664 million at Dec. 31, 2019 |
The net loss narrowed chiefly because the company recorded a $3.845 million noncash gain from remeasuring its warrant liability, versus a $0.529 million gain in Q1 2019. The company remained loss-making, so profit margins are not meaningful. R&D costs rose with clinical activity, manufacturing, research agreements and staffing; G&A increased mainly with payroll, stock compensation and insurance.
Net cash from financing was $5.291 million, primarily from the February offering. Current assets were $13.787 million and current liabilities $3.235 million, or approximately 4.3 times current-liability coverage. The filing reports no conventional borrowings; liabilities include a $6.697 million warrant liability and operating lease liabilities. Operating lease liabilities had a $0.355 million present value. The company reported an accumulated deficit of $40.8 million and substantial doubt about its ability to continue as a going concern, citing dependence on future financing and lack of operating revenue.
Material changes, outlook and risks
- In February 2020, Moleculin sold 7.5 million shares with warrants for gross proceeds of $6.0 million; the cash flow statement reports $5.291 million of financing proceeds for the quarter. Common shares outstanding increased from 45.7 million at year-end to 53.2 million at March 31.
- After quarter-end, the company sold 7.17 million shares through its ATM program from April 8–16 for net proceeds of $10.0 million. It reported 60.4 million shares outstanding at May 6. Management estimated cash, including those ATM proceeds, would fund planned operations into Q1 2021, absent additional equity financing; this estimate depends on market conditions, spending and trial progress.
- Management said COVID-19 had caused limited interruption to drug supply and monitoring access at some Polish trial sites, with no material impact then evident, but warned disruptions could worsen. The company also identified potential effects on clinical enrollment, research partners, regulators, supply and its ability to raise capital.
- Management described the US Annamycin Phase 1 portion as having reached key safety endpoints and the Polish dose-escalation trial as continuing. It reported no cardiotoxicity to date in treated patients. WP1220 Phase 1 was complete, with a possible Phase 2 planned. The company was evaluating WP1122 for antiviral potential; cited 2-DG laboratory results were preliminary and not peer reviewed, and do not establish that WP1122 is effective in patients.
- On May 1, 2020, the SEC ordered a temporary trading suspension, effective May 4 through May 15, citing questions about the accuracy and adequacy of marketplace information about the company and its securities. The company said it petitioned to terminate the suspension; an extension remained possible.
- Disclosure controls were assessed as ineffective because of a material weakness in segregation of duties, although the company described remediation steps and additional financial-statement procedures. COVID-19 uncertainty, financing needs, clinical and regulatory outcomes, third-party manufacturing, and intellectual-property risks remain material. No legal proceedings were reported.
Important facts for investors to verify
- Current cash runway, actual spending versus management’s estimate, and whether further financing is needed; assess the dilution from the February and April share issuances and outstanding warrants.
- Developments concerning the SEC trading suspension and any further SEC statements or company disclosures addressing the questions raised.
- Clinical-trial enrollment, safety and efficacy updates, regulatory milestones, and whether planned studies and timelines proceed as expected.
- Whether COVID-19 affects trial access, drug supply, research activity or capital-raising capacity, and whether WP1122 antiviral findings are validated in further studies.
- Progress in remediating the disclosed material weakness and any changes to the company’s going-concern assessment.